162 related articles for article (PubMed ID: 32185865)
1. Inflammation in areas of fibrosis: The DeKAF prospective cohort.
Matas AJ; Helgeson ES; Gaston R; Cosio F; Mannon R; Kasiske BL; Hunsicker L; Gourishankar S; Rush D; Michael Cecka J; Connett J; Grande JP
Am J Transplant; 2020 Sep; 20(9):2509-2521. PubMed ID: 32185865
[TBL] [Abstract][Full Text] [Related]
2. i-IFTA and chronic active T cell-mediated rejection: A tale of 2 (DeKAF) cohorts.
Helgeson ES; Mannon R; Grande J; Gaston RS; Cecka MJ; Kasiske BL; Rush D; Gourishankar S; Cosio F; Hunsicker L; Connett J; Matas AJ
Am J Transplant; 2021 May; 21(5):1866-1877. PubMed ID: 33052625
[TBL] [Abstract][Full Text] [Related]
3. The causes, significance and consequences of inflammatory fibrosis in kidney transplantation: The Banff i-IFTA lesion.
Nankivell BJ; Shingde M; Keung KL; Fung CL; Borrows RJ; O'Connell PJ; Chapman JR
Am J Transplant; 2018 Feb; 18(2):364-376. PubMed ID: 29194971
[TBL] [Abstract][Full Text] [Related]
4. Challenges Posed by the Banff Classification: Diagnosis and Treatment of Chronic Active T-Cell-Mediated Rejection.
Yamamoto I; Kawabe M; Hayashi A; Kobayashi A; Yamamoto H; Yokoo T
Nephron; 2023; 147 Suppl 1():74-79. PubMed ID: 36928337
[TBL] [Abstract][Full Text] [Related]
5. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.
Haas M; Loupy A; Lefaucheur C; Roufosse C; Glotz D; Seron D; Nankivell BJ; Halloran PF; Colvin RB; Akalin E; Alachkar N; Bagnasco S; Bouatou Y; Becker JU; Cornell LD; Duong van Huyen JP; Gibson IW; Kraus ES; Mannon RB; Naesens M; Nickeleit V; Nickerson P; Segev DL; Singh HK; Stegall M; Randhawa P; Racusen L; Solez K; Mengel M
Am J Transplant; 2018 Feb; 18(2):293-307. PubMed ID: 29243394
[TBL] [Abstract][Full Text] [Related]
6. Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas.
Halloran PF; Matas A; Kasiske BL; Madill-Thomsen KS; Mackova M; Famulski KS
Am J Transplant; 2019 May; 19(5):1356-1370. PubMed ID: 30417539
[TBL] [Abstract][Full Text] [Related]
7. T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts.
Lefaucheur C; Gosset C; Rabant M; Viglietti D; Verine J; Aubert O; Louis K; Glotz D; Legendre C; Duong Van Huyen JP; Loupy A
Am J Transplant; 2018 Feb; 18(2):377-390. PubMed ID: 29086461
[TBL] [Abstract][Full Text] [Related]
8. Significance of revised criteria for chronic active T cell-mediated rejection in the 2017 Banff classification: Surveillance by 1-year protocol biopsies for kidney transplantation.
Nakagawa K; Tsuchimoto A; Ueki K; Matsukuma Y; Okabe Y; Masutani K; Unagami K; Kakuta Y; Okumi M; Nakamura M; Nakano T; Tanabe K; Kitazono T;
Am J Transplant; 2021 Jan; 21(1):174-185. PubMed ID: 32484280
[TBL] [Abstract][Full Text] [Related]
9. Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes.
Modena BD; Kurian SM; Gaber LW; Waalen J; Su AI; Gelbart T; Mondala TS; Head SR; Papp S; Heilman R; Friedewald JJ; Flechner SM; Marsh CL; Sung RS; Shidban H; Chan L; Abecassis MM; Salomon DR
Am J Transplant; 2016 Jul; 16(7):1982-98. PubMed ID: 26990570
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of the DeKAF cross-sectional cohort study.
Matas AJ; Fieberg A; Mannon RB; Leduc R; Grande J; Kasiske BL; Cecka M; Gaston R; Hunsicker L; Connett J; Cosio F; Gourishankar S; Rush D
Am J Transplant; 2019 May; 19(5):1432-1443. PubMed ID: 30506642
[TBL] [Abstract][Full Text] [Related]
11. Does tubulitis without interstitial inflammation represent borderline acute T cell mediated rejection?
Nankivell BJ; P'Ng CH; Chapman JR
Am J Transplant; 2019 Jan; 19(1):132-144. PubMed ID: 29687946
[TBL] [Abstract][Full Text] [Related]
12. Significance of Perivascular Aggregates in Kidney Allografts: Evaluation of 1-Year Protocol Biopsies Using Recent Banff Classification.
Masutani K; Nakagawa K; Matsukuma Y; Ueki K; Ataka E; Tsuchimoto A; Okabe Y; Nakamura M; Kitazono T; Nakano T
Transplant Proc; 2024 Apr; 56(3):499-504. PubMed ID: 38320868
[TBL] [Abstract][Full Text] [Related]
13. Donor-specific anti-HLA antibodies in pediatric renal transplant recipients with creeping creatinine: Prevalence, histological correlations, and impact on patient and graft survival.
Monteverde ML; Chaparro A; Goldberg J; Marcos CY; Padros K; Balbarrey Z; Briones L; Rush D
Pediatr Transplant; 2015 Nov; 19(7):684-90. PubMed ID: 26212912
[TBL] [Abstract][Full Text] [Related]
14. Inflammation in Early Kidney Allograft Surveillance Biopsies With and Without Associated Tubulointerstitial Chronic Damage as a Predictor of Fibrosis Progression and Development of De Novo Donor Specific Antibodies.
García-Carro C; Dörje C; Åsberg A; Midtvedt K; Scott H; Reinholt FP; Holdaas H; Seron D; Reisæter AV
Transplantation; 2017 Jun; 101(6):1410-1415. PubMed ID: 27163535
[TBL] [Abstract][Full Text] [Related]
15. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.
Loupy A; Haas M; Solez K; Racusen L; Glotz D; Seron D; Nankivell BJ; Colvin RB; Afrouzian M; Akalin E; Alachkar N; Bagnasco S; Becker JU; Cornell L; Drachenberg C; Dragun D; de Kort H; Gibson IW; Kraus ES; Lefaucheur C; Legendre C; Liapis H; Muthukumar T; Nickeleit V; Orandi B; Park W; Rabant M; Randhawa P; Reed EF; Roufosse C; Seshan SV; Sis B; Singh HK; Schinstock C; Tambur A; Zeevi A; Mengel M
Am J Transplant; 2017 Jan; 17(1):28-41. PubMed ID: 27862883
[TBL] [Abstract][Full Text] [Related]
16. Early allograft inflammation and scarring associate with graft dysfunction and poor outcomes in renal transplant recipients with delayed graft function: a prospective single center cohort study.
Cherukuri A; Mehta R; Sood P; Hariharan S
Transpl Int; 2018 Dec; 31(12):1369-1379. PubMed ID: 30007072
[TBL] [Abstract][Full Text] [Related]
17. Renal graft survival according to Banff 2013 classification in indication biopsies.
Arias-Cabrales C; Redondo-Pachón D; Pérez-Sáez MJ; Gimeno J; Sánchez-Güerri I; Bermejo S; Sierra A; Burballa C; Mir M; Crespo M; Pascual J
Nefrologia; 2016; 36(6):660-666. PubMed ID: 27595515
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic active T cell-mediated rejection after kidney transplantation: A retrospective cohort study of 37 transplants.
Noguchi H; Matsukuma Y; Nakagawa K; Ueki K; Tsuchimoto A; Nakano T; Sato Y; Kaku K; Okabe Y; Nakamura M
Nephrology (Carlton); 2022 Jul; 27(7):632-638. PubMed ID: 35478476
[TBL] [Abstract][Full Text] [Related]
19. Cell mediated rejection revisited: Past, current, and future directions.
Hara S
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():45-51. PubMed ID: 29968416
[TBL] [Abstract][Full Text] [Related]
20. A Banff Component Scoring-based Histologic Assessment of Bortezomib-based Antibody-mediated Rejection Therapy.
Sadaka B; Ejaz NS; Shields AR; Cardi MA; Wadih G; Witte D; Abu Jawdeh BG; Alloway RR; Woodle ES
Transplantation; 2015 Aug; 99(8):1691-9. PubMed ID: 25803498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
